investorscraft@gmail.com

Intrinsic value of Pacira BioSciences, Inc. (PCRX)

Previous Close$58.89
Intrinsic Value
Upside potential
Previous Close
$58.89

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh54.82 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %26.0NaN
Revenue, $542NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m452NaN
Operating income, $m90NaN
EBITDA, $m118NaN
Interest expense (income), $mNaN
Earnings before tax, $m56NaN
Tax expense, $m14NaN
Net income, $m42NaN

BALANCE SHEET

Cash and short-term investments, $m656NaN
Total assets, $m2075NaN
Adjusted assets (=assets-cash), $m1419NaN
Average production assets, $m721NaN
Working capital, $m345NaN
Total debt, $m1129NaN
Total liabilities, $m1345NaN
Total equity, $m730NaN
Debt-to-equity ratio1.547NaN
Adjusted equity ratio0.322NaN

CASH FLOW

Net income, $m42NaN
Depreciation, amort., depletion, $m29NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m126NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-46NaN
Free cash flow, $m172NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m345
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount